Gilteritinib Maintenance Reduces Relapse in MRD+ AML Gilteritinib Maintenance Reduces Relapse in MRD+ AML

Patients with acute myeloid leukemia and who have minimal residual disease following hematopoietic cell transplantation have a reduced risk of relapse with gilteritinib maintenance therapy.MDedge News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news